Lessons learned from hyponatremia associated with hyperthermic intraperitoneal chemoperfusion with oxaliplatin.
Nguyen
Minhtri K
MK
Department of Medicine, University of California at Los Angeles, California, USA. mtnguyen@mednet.ucla.edu
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001786:Blood Glucose / Q000378:metabolism; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects; D007010:Hyponatremia / Q000209:etiology* / Q000378:metabolism*; D007263:Infusions, Parenteral / Q000009:adverse effects / Q000379:methods; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077150:Oxaliplatin; D010949:Plasma / Q000378:metabolism; D012964:Sodium / Q000378:metabolism; D014882:Water-Electrolyte Balance
D000970:Antineoplastic Agents; D001786:Blood Glucose; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D012964:Sodium